This strategy may also be promise for the treatment of other types of cancer characterized by frequent amplification of TBC1D31 (> 50%; Figure S1d, Supporting Information), such as uveal melanoma, ovarian cancer, and uterine carcinosarcoma. This evidence concerns the gene TBC1D31 and uveal melanoma.